PhRMA member companies invested nearly $80 billion in R&D last year
By Tim McClung | July 18, 2019
Last year, PhRMA member companies invested a record-setting $79.6 billion in research and development (R&D) according to the 2019 PhRMA member annual survey.
Read More
Setting the record straight on international reference pricing
By Kevin Haninger | July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...
Read More
Four states adopt first-in-the-nation laws to protect patients from surprise insurer practices
By Nick McGee | July 15, 2019
West Virginia, Virginia, Arizona and Illinois recently became the first states in America to adopt patient-centered legislation to bring relief and more predictability to patients facing high...
Read More
New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?
By Priscilla VanderVeer | July 9, 2019
For the last two years, our Let’s Talk About Cost campaign has sought to answer questions people have about their medicine costs and advance a dialogue on how we can make medicines more affordable...
Read More
Study finds hospitals continue to mark up medicines up to 500% of their cost
By Holly Campbell | July 9, 2019
A new analysis from the Moran Company found hospitals continue to charge, on average, five times their cost for medicines, driving up cost sharing and premiums for patients across the country....
Read More
Three reasons why the latest Rx Savings Solutions analysis is misleading
By Holly Campbell | July 2, 2019
Yesterday, multiple news outlets featured data from Rx Savings Solutions on medicine price trends. These data reflect list price increases, ignoring the significant rebates and discounts on...
Read More
No matter how you structure it, government arbitration is wrong for Medicare drug coverage
By Nicole Longo | June 27, 2019
Despite concerns from a broad group of stakeholders, some in Washington continue to push for imposing government arbitration on Medicare drug coverage to set the price of a medicine....
Read More
PhRMA responds to Florida’s request for information on drug importation
By Tiffany Haverly | June 26, 2019
PhRMA remains committed to working with lawmakers to ensure patients can afford and access their medicines, but importation schemes that put patient safety at risk will never be the right approach.
Read More
IP Explained: What is Section 101 and why reforms are needed
By Tom Wilbur | June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...
Read More
"If Washington isn’t careful, we might leave innovation behind"
By Robert Zirkelbach | June 24, 2019
“Trying to make medications more affordable is important, but if Washington isn’t careful, we might leave innovation behind.” This is the message we heard from Amy, a Voters for Cures advocate...
Read More
Medicare Monday (100)
340B Spotlight (42)
Cost & Consequence (0)
